Navigation Links
Biomerix Granted CE Mark for its REVIVE™ Soft Tissue Repair Mesh
Date:1/24/2011

FREMONT, Calif., Jan. 24, 2011 /PRNewswire/ -- Biomerix Corporation announced today that it has received CE Mark approval for its REVIVE™ soft tissue repair mesh allowing for the marketing of REVIVE in all European Union member (EU) states.    REVIVE received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in January 2009.

REVIVE is constructed of the Biomerix Biomaterial™, a proprietary, biointegrative synthetic tissue scaffold.  This unique structure is designed to play a role similar to that of the body's extracellular matrix, supporting organized tissue ingrowth.  The device is designed for repair and reinforcement in a variety of soft tissue procedures such as inguinal hernias.

Over 700,000 inguinal hernia repair procedures are performed annually in Europe.  Inguinal hernias occur when soft tissue, usually part of the intestines, protrudes through a weak point or tear in the lower abdominal wall.  Synthetic mesh is commonly used to reinforce the repair and support the surrounding tissue.  REVIVE is designed to facilitate robust tissue ingrowth, while minimizing the scarring response typically associated with implantation of a mesh.  Mesh contraction and intense scarring can lead to persistent groin pain.  Initial feedback from users of REVIVE has confirmed excellent ease of use and conformability to the anatomy.  The soft, pliable nature of the mesh easily adapts to the anatomy allowing for easy delivery, positioning and fixation of the mesh.

"This latest approval represents another important milestone in Biomerix's plans to develop innovative products based on its proprietary materials and capabilities," said Kenneth G. Hayes, President and CEO of Biomerix Corporation.  "REVIVE will be distributed in the EU by Medline Industries pursuant to our exclusive distribution agreement."

About Biomerix

Biomerix Corporation develops and manufactures novel and proprietary materials to meet the needs of the medical, industrial, and consumer markets.  Founded in 2001, Biomerix began developing a new class of polymeric material designed to support the tissue healing process.  By 2004, the Company achieved a significant breakthrough and created the proprietary Biomerix Biomaterial™, a revolutionary biointegrative synthetic tissue scaffold.  The Biomerix Biomaterial is a non-resorbable, cross linked, reticulated, polycarbonate polyurethane-urea consisting of an open-cell, three-dimensional, interconnected macroporous structure.  This unique scaffold translates into an ability to support predictable, organized fibrovascular tissue ingrowth.  The Biomerix Biomaterial is designed to play a role similar to the body's extracellular matrix (ECM), through the main phases of inflammation, proliferation, and remodeling.

To maximize the value of its material platform technology and capabilities, Biomerix has implemented a multifaceted business model.  The Company selectively develops and manufactures OEM finished medical devices using the Biomerix Biomaterial, supplies the Biomerix Biomaterial as a component for other medical devices; and collaboratively designs and develops custom materials with select business partners. For more information please call 888.308.3620 or visit www.biomerix.com.


'/>"/>
SOURCE Biomerix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biomerix Ventral Hernia Repair Mesh Receives FDA 510(k) Clearance
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
4. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
5. Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
6. Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
7. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
8. Emphasys Medical Granted Expedited Review From FDA for Zephyr(R) Endobronchial Valve
9. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
10. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
11. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 ... performance ratings for global supply chains, has published the first annual edition ... CSR performance of more than 20,400 companies evaluated by EcoVadis, based on ... 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of ... its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his ... July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming ...
(Date:10/13/2017)... ... , ... Apple Rehab Shelton Lakes , which specializes in the delivery ... as part of a disaster drill on October 3rd. , Apple Rehab participated with ... Manager, as well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
Breaking Medicine News(10 mins):